Brokerages Set Metagenomi, Inc. (NASDAQ:MGX) Price Target at $16.67

Shares of Metagenomi, Inc. (NASDAQ:MGX) have been given a consensus rating of “Moderate Buy” by the seven analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $16.67.

Several brokerages have issued reports on MGX. HC Wainwright raised their price objective on Metagenomi from $7.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, December 10th. Chardan Capital reissued a “buy” rating and set a $15.00 price target on shares of Metagenomi in a report on Wednesday, November 20th.

Institutional Investors Weigh In On Metagenomi

A number of institutional investors have recently added to or reduced their stakes in the business. Spire Wealth Management purchased a new stake in Metagenomi in the 4th quarter valued at approximately $267,000. Fortitude Advisory Group L.L.C. acquired a new stake in shares of Metagenomi during the 4th quarter valued at approximately $273,000. SG Americas Securities LLC acquired a new stake in shares of Metagenomi during the 4th quarter valued at approximately $43,000. Marquette Asset Management LLC acquired a new stake in shares of Metagenomi during the 4th quarter valued at approximately $184,000. Finally, Virtu Financial LLC acquired a new position in shares of Metagenomi during the 3rd quarter worth approximately $33,000.

Metagenomi Stock Down 0.4 %

Shares of MGX stock opened at $2.76 on Friday. The stock’s 50-day moving average is $2.99 and its two-hundred day moving average is $2.86. Metagenomi has a 1 year low of $1.61 and a 1 year high of $12.74.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.